Outlook Therapeutics Inc (NASDAQ:OTLK) Has Recovered -76.35 Percent This Year, But Further Gains Of -428.57% Are Not Out Of The Question.

In last trading session, Outlook Therapeutics Inc (NASDAQ:OTLK) saw 0.32 million shares changing hands with its beta currently measuring 0.28. Company’s recent per share price level of $1.75 trading at $0.08 or 4.48% at ring of the bell on the day assigns it a market valuation of $57.09M. That closing price of OTLK’s stock is at a discount of -428.57% from its 52-week high price of $9.25 and is indicating a premium of 50.29% from its 52-week low price of $0.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 423.12K if we extend that period to 3-months.

For Outlook Therapeutics Inc (OTLK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.47 in the current quarter.

Outlook Therapeutics Inc (NASDAQ:OTLK) trade information

Upright in the green during last session for gaining 4.48%, in the last five days OTLK remained trading in the green while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $1.75 price level, adding 14.0% to its value on the day. Outlook Therapeutics Inc’s shares saw a change of -7.41% in year-to-date performance and have moved 14.38% in past 5-day. Outlook Therapeutics Inc (NASDAQ:OTLK) showed a performance of 27.74% in past 30-days. Number of shares sold short was 3.58 million shares which calculate 10.15 days to cover the short interests.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.53M for the same. And 5 analysts are in estimates of company making revenue of 7.41M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.59% during past 5 years.

Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders

Insiders are in possession of 36.42% of company’s total shares while institution are holding 16.64 percent of that, with stock having share float percentage of 26.17%. Investors also watch the number of corporate investors in a company very closely, which is 16.64% institutions for Outlook Therapeutics Inc that are currently holding shares of the company. GREAT POINT PARTNERS LLC is the top institutional holder at OTLK for having 1.7 million shares of worth $12.56 million. And as of 2024-06-30, it was holding 7.3255 of the company’s outstanding shares.

The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 1.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9721 of outstanding shares, having a total worth of $11.95 million.

On the other hand, iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 542.2 shares of worth $0.95 million or 1.69% of the total outstanding shares. The later fund manager was in possession of 442.51 shares on Dec 31, 2024 , making its stake of worth around $0.77 million in the company or a holder of 1.38% of company’s stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.